The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome
about
Melanoma-restricted genesKnock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cellsDifferential expression of PRAMEL1, a cancer/testis antigen, during spermatogenesis in the mouseExternal validation suggests Integrin beta 3 as prognostic biomarker in serous ovarian adenocarcinomasMelanoma: tumor microenvironment and new treatments.T-cell-based therapies for malignancy and infection in childhood.IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastomaIncreased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promotersIncreased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma.Immunotherapy targets in pediatric cancer.Rates of MAGE-A3 and PRAME expressing tumors in FFPE tissue specimens from bladder cancer patients: potential targets for antigen-specific cancer immunotherapeutics.Lung cancer: Biology and treatment options.Immunotherapy of neuroblastoma: present, past and future.PRAME expression in hairy cell leukemia.PRAME expression and clinical outcome of breast cancerCancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.Molecular characterization and classification of neuroblastoma.An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia.Vaccines as consolidation therapy for myeloid leukemia.Retinoids: novel immunomodulators and tumour-suppressive agents?The graft-versus-neuroblastoma effect of allogeneic hematopoietic stem cell transplantation, a review of clinical and experimental evidence and a perspective on mechanisms.Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.Tumor associated antigen PRAME is a marker of favorable prognosis in childhood acute myeloid leukemia patients and modifies the expression of S100A4, Hsp 27, p21, IL-8 and IGFBP-2 in vitro and in vivo.Retinoic acid signaling and neuronal differentiation.A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomasIdentification of Preferentially Expressed Antigen of Melanoma as a Potential Tumor Suppressor in Lung Adenocarcinoma.Cancer-testis antigens expressed in osteosarcoma identified by gene microarray correlate with a poor patient prognosis.Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma.BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha.Expression of the tumour suppressor gene CADM1 is associated with favourable outcome and inhibits cell survival in neuroblastoma.Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine.Impact of Preferentially Expressed Antigen of Melanoma on the Prognosis of Hepatocellular Carcinoma.The human EKC/KEOPS complex is recruited to Cullin2 ubiquitin ligases by the human tumour antigen PRAME.
P2860
Q24793788-9AE4AA2B-C461-4681-89CA-C142FFDC27E8Q28486108-57C1EE24-AAA0-47DA-9A7D-04759DD2A54BQ28587770-1363AFFC-A451-4245-BFB8-12ED013DC0CAQ33506176-34A406BE-8129-4E92-8B1F-306C89DFD5C0Q33675676-A487F46D-26EF-49C3-9282-565C111CC81CQ33750862-D203807B-FC56-4973-AE17-A0D99D795BE4Q34447613-D47834E2-171E-405B-92A5-A6021CA17524Q34935239-C8D8FF19-CC9A-4649-B9E2-A197C5118E74Q35214905-92A13815-278F-4544-9642-44C88E82E153Q35543740-906BF334-BE4A-4F80-83CF-B8987697887DQ35971029-7F33836D-2621-44AC-B528-72ED1C9BE8ECQ36095397-D90964E6-A6C6-42F7-961C-A0E020F66DFEQ36328370-99436B9F-166A-4243-AA4F-EEA1E1DC7281Q36453273-07F197C3-479A-41C4-9D4A-938E35C7CA76Q36748859-B9B6BD04-972E-4BB2-A55C-BD2B6992B8CFQ36858038-F1C8FF1F-8392-44B1-AFFC-52C3B99D3ACCQ37082518-84650211-9ADD-44E2-A089-314FCAE3CCF4Q37381700-05B5E6F0-1EB9-4D05-B299-5FFC206B5FDAQ37515355-E24655A1-98AE-4B29-A621-C1C6CAAA05ABQ37663934-AA79253A-D661-402B-8FD5-0C6B120D02A4Q37783631-D2CEFE8B-D708-414D-8A63-05CB46E831D5Q37842342-B62EC17D-066E-4817-ADBD-D7DF9F527930Q38009350-FC6C6643-07DC-40C9-946E-AB40F94DDA0CQ38243215-5A6BE359-C8FC-4BF6-80BC-85BB17FA130BQ38262786-D8672497-D1E9-4BFD-9DD6-DFD04583DE1EQ38291355-0F1F982D-B424-4350-AE7C-FC6245330853Q38307264-02DFA6D1-6DD8-44ED-BCCD-26EB8D9269D6Q38719407-7456571D-A297-448F-B529-5A298F219BB5Q38756704-23342490-9DF3-4970-96F6-B9C301AD8ED2Q38767458-E22E595D-488D-4DE4-9B7F-5C12F01FEFFBQ39456290-B74E7096-BEC9-4895-BDE1-202E10FD70E7Q39472050-A39A3BA2-99C5-452C-AFF9-7659C7B23668Q39546197-067A71A3-A5F6-4692-81D1-7E1EAA20B164Q39643643-36A73750-514D-4D94-A10F-F53E3771B71FQ39656321-7B6FB79F-46DA-46F2-AF76-7C98B49109C1Q39781613-9C3A2A33-6C18-457F-9549-B41273C68646Q40034808-150BCD30-BF62-4B54-A0E3-FB3F007C9398Q40167750-6D00D79C-FE16-460A-9BD0-8D6E4C39C43EQ42211126-5197E4EC-DD76-44D3-8181-6D431D8ED89AQ42274601-81D4B50F-A9FC-4685-B0EA-2D9C0D961D9F
P2860
The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
The tumor-associated antigen P ...... d associated with poor outcome
@ast
The tumor-associated antigen P ...... d associated with poor outcome
@en
The tumor-associated antigen P ...... d associated with poor outcome
@nl
type
label
The tumor-associated antigen P ...... d associated with poor outcome
@ast
The tumor-associated antigen P ...... d associated with poor outcome
@en
The tumor-associated antigen P ...... d associated with poor outcome
@nl
prefLabel
The tumor-associated antigen P ...... d associated with poor outcome
@ast
The tumor-associated antigen P ...... d associated with poor outcome
@en
The tumor-associated antigen P ...... d associated with poor outcome
@nl
P2093
P3181
P1476
The tumor-associated antigen P ...... d associated with poor outcome
@en
P2093
André Oberthuer
Barbara Hero
Frank Berthold
Matthias Fischer
Rüdiger Spitz
P304
P3181
P356
10.1158/1078-0432.CCR-03-0813
P407
P577
2004-07-01T00:00:00Z